Skip to main content
NCBI home page
The American Journal of Pathology logoLink to The American Journal of Pathology
. 1990 Dec;137(6):1491–1500.

Proliferation markers Ki-67 and p105 in soft-tissue lesions. Correlation with DNA flow cytometric characteristics.

S A Swanson 1, J J Brooks 1
PMCID: PMC1877737  PMID: 1979714

Abstract

Frozen tissue immunoreactivity with Ki-67, a monoclonal antibody that recognizes a nuclear antigen in nonresting or proliferating cells, was compared to DNA flow cytometry results (from fresh tissue) in a diverse group of 60 soft-tissue lesions. Both DNA index and Ki-67 score were independently reported to be associated with grade and prognosis in sarcomas, but no direct comparison of these two variables was made. It was attempted to measure proliferative activity in fixed paraffin-embedded tissues immunohistochemically in a subset of lesions using an antibody to another nuclear proliferation antigen, p105. Lesions were given a grade according to lesion category (reactive, 1; benign, 2; low-grade malignant, 3; and high-grade malignant, 4). Ki-67 reactivity correlated relatively well with this grading system (r = 0.59); benign lesions usually exhibited a low Ki-67 score and malignant lesions usually but not always exhibited a high score. For example, some malignant fibrous histiocytomas contained only rare positive cells. Some disparity between Ki-67 score and grade and within histologic types indicates some independence from these features, a fact that may be important when correlation with prognosis is performed. However Ki-67 did not correlate well with flow data such as percentage S phase (r = 0.30), percentage S + G2M phases (r = 0.37), or DNA index (r = 0.39). This probably is due to the fact that Ki-67 also marks cells in the G1 phase, whereas these are excluded in flow data analyses. Anti-p105 highlighted almost all nuclei in all cases tested, including fibromatosis, and did not correlate with Ki-67 score, histologic grade or DNA flow cytometric data. Results with p105 could not be favorably affected by titration experiments. It is reasonable to conclude that the Ki-67 score is a variable related to but independent of histologic grade, histologic type, and DNA flow values. Whether it is prognostically important in human sarcomas, as has been suggested, awaits further clinicopathologic study.

Full text

PDF
1491

Images in this article

1495Figure 1
on p.1495
1495Figure 2
on p.1495
1496Figure 3
on p.1496

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Barnard N. J., Hall P. A., Lemoine N. R., Kadar N. Proliferative index in breast carcinoma determined in situ by Ki67 immunostaining and its relationship to clinical and pathological variables. J Pathol. 1987 Aug;152(4):287–295. doi: 10.1002/path.1711520407. [DOI] [PubMed] [Google Scholar]
  2. Burger P. C., Shibata T., Kleihues P. The use of the monoclonal antibody Ki-67 in the identification of proliferating cells: application to surgical neuropathology. Am J Surg Pathol. 1986 Sep;10(9):611–617. doi: 10.1097/00000478-198609000-00003. [DOI] [PubMed] [Google Scholar]
  3. Clevenger C. V., Epstein A. L., Bauer K. D. Modulation of the nuclear antigen p105 as a function of cell-cycle progression. J Cell Physiol. 1987 Mar;130(3):336–343. doi: 10.1002/jcp.1041300305. [DOI] [PubMed] [Google Scholar]
  4. Fitzgibbons P. L., Appley A. J., Turner R. R., Bishop P. C., Parker J. W., Breeze R. E., Weiss M. H., Apuzzo M. L. Flow cytometric analysis of pituitary tumors. Correlation of nuclear antigen p105 and DNA content with clinical behavior. Cancer. 1988 Oct 15;62(8):1556–1560. doi: 10.1002/1097-0142(19881015)62:8<1556::aid-cncr2820620816>3.0.co;2-o. [DOI] [PubMed] [Google Scholar]
  5. Garcia R. L., Coltrera M. D., Gown A. M. Analysis of proliferative grade using anti-PCNA/cyclin monoclonal antibodies in fixed, embedded tissues. Comparison with flow cytometric analysis. Am J Pathol. 1989 Apr;134(4):733–739. [PMC free article] [PubMed] [Google Scholar]
  6. Gerdes J., Dallenbach F., Lennert K., Lemke H., Stein H. Growth fractions in malignant non-Hodgkin's lymphomas (NHL) as determined in situ with the monoclonal antibody Ki-67. Hematol Oncol. 1984 Oct-Dec;2(4):365–371. doi: 10.1002/hon.2900020406. [DOI] [PubMed] [Google Scholar]
  7. Gerdes J., Lelle R. J., Pickartz H., Heidenreich W., Schwarting R., Kurtsiefer L., Stauch G., Stein H. Growth fractions in breast cancers determined in situ with monoclonal antibody Ki-67. J Clin Pathol. 1986 Sep;39(9):977–980. doi: 10.1136/jcp.39.9.977. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Gerdes J., Lemke H., Baisch H., Wacker H. H., Schwab U., Stein H. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol. 1984 Oct;133(4):1710–1715. [PubMed] [Google Scholar]
  9. Gerdes J., Pickartz H., Brotherton J., Hammerstein J., Weitzel H., Stein H. Growth fractions and estrogen receptors in human breast cancers as determined in situ with monoclonal antibodies. Am J Pathol. 1987 Dec;129(3):486–492. [PMC free article] [PubMed] [Google Scholar]
  10. Gerdes J., Stein H., Pileri S., Rivano M. T., Gobbi M., Ralfkiaer E., Nielsen K. M., Pallesen G., Bartels H., Palestro G. Prognostic relevance of tumour-cell growth fraction in malignant non-Hodgkin's lymphomas. Lancet. 1987 Aug 22;2(8556):448–449. doi: 10.1016/s0140-6736(87)90977-9. [DOI] [PubMed] [Google Scholar]
  11. Hall P. A., Richards M. A., Gregory W. M., d'Ardenne A. J., Lister T. A., Stansfeld A. G. The prognostic value of Ki67 immunostaining in non-Hodgkin's lymphoma. J Pathol. 1988 Mar;154(3):223–235. doi: 10.1002/path.1711540305. [DOI] [PubMed] [Google Scholar]
  12. Helin M. L., Helle M. J., Helin H. J., Isola J. J. Proliferative activity and steroid receptors determined by immunohistochemistry in adjacent frozen sections of 102 breast carcinomas. Arch Pathol Lab Med. 1989 Aug;113(8):854–857. [PubMed] [Google Scholar]
  13. Hsu S. M., Raine L., Fanger H. A comparative study of the peroxidase-antiperoxidase method and an avidin-biotin complex method for studying polypeptide hormones with radioimmunoassay antibodies. Am J Clin Pathol. 1981 May;75(5):734–738. doi: 10.1093/ajcp/75.5.734. [DOI] [PubMed] [Google Scholar]
  14. Kamel O. W., Franklin W. A., Ringus J. C., Meyer J. S. Thymidine labeling index and Ki-67 growth fraction in lesions of the breast. Am J Pathol. 1989 Jan;134(1):107–113. [PMC free article] [PubMed] [Google Scholar]
  15. Kaudewitz P., Braun-Falco O., Ernst M., Landthaler M., Stolz W., Gerdes J. Tumor cell growth fractions in human malignant melanomas and the correlation to histopathologic tumor grading. Am J Pathol. 1989 May;134(5):1063–1068. [PMC free article] [PubMed] [Google Scholar]
  16. Kiyabu M. T., Bishop P. C., Parker J. W., Turner R. R., Fitzgibbons P. L. Smooth muscle tumors of the gastrointestinal tract. Flow cytometric quantitation of DNA and nuclear antigen content and correlation with histologic grade. Am J Surg Pathol. 1988 Dec;12(12):954–960. [PubMed] [Google Scholar]
  17. Kreicbergs A., Tribukait B., Willems J., Bauer H. C. DNA flow analysis of soft tissue tumors. Cancer. 1987 Jan 1;59(1):128–133. doi: 10.1002/1097-0142(19870101)59:1<128::aid-cncr2820590126>3.0.co;2-g. [DOI] [PubMed] [Google Scholar]
  18. Kroese M. C., Rutgers D. H., Wils I. S., Van Unnik J. A., Roholl P. J. The relevance of the DNA index and proliferation rate in the grading of benign and malignant soft tissue tumors. Cancer. 1990 Apr 15;65(8):1782–1788. doi: 10.1002/1097-0142(19900415)65:8<1782::aid-cncr2820650819>3.0.co;2-i. [DOI] [PubMed] [Google Scholar]
  19. Lellé R. J., Heidenreich W., Stauch G., Gerdes J. The correlation of growth fractions with histologic grading and lymph node status in human mammary carcinoma. Cancer. 1987 Jan 1;59(1):83–88. doi: 10.1002/1097-0142(19870101)59:1<83::aid-cncr2820590119>3.0.co;2-i. [DOI] [PubMed] [Google Scholar]
  20. Matsumura K., Tsuji T., Shinozaki F., Sasaki K., Takahashi M. Immunohistochemical determination of growth fraction in human tumors. Pathol Res Pract. 1989 Jun;184(6):609–613. doi: 10.1016/S0344-0338(89)80166-9. [DOI] [PubMed] [Google Scholar]
  21. McGurrin J. F., Doria M. I., Jr, Dawson P. J., Karrison T., Stein H. O., Franklin W. A. Assessment of tumor cell kinetics by immunohistochemistry in carcinoma of breast. Cancer. 1987 May 15;59(10):1744–1750. doi: 10.1002/1097-0142(19870515)59:10<1744::aid-cncr2820591012>3.0.co;2-d. [DOI] [PubMed] [Google Scholar]
  22. Pileri S., Gerdes J., Rivano M., Tazzari P. L., Magnani M., Gobbi M., Stein H. Immunohistochemical determination of growth fractions in human permanent cell lines and lymphoid tumours: a critical comparison of the monoclonal antibodies OKT9 and Ki-67. Br J Haematol. 1987 Mar;65(3):271–276. doi: 10.1111/j.1365-2141.1987.tb06853.x. [DOI] [PubMed] [Google Scholar]
  23. Radio S. J., Wooldridge T. N., Linder J. Flow cytometric DNA analysis of malignant fibrous histiocytoma and related fibrohistiocytic tumors. Hum Pathol. 1988 Jan;19(1):74–77. doi: 10.1016/s0046-8177(88)80319-8. [DOI] [PubMed] [Google Scholar]
  24. Sasaki K., Matsumura K., Tsuji T., Shinozaki F., Takahashi M. Relationship between labeling indices of Ki-67 and BrdUrd in human malignant tumors. Cancer. 1988 Sep 1;62(5):989–993. doi: 10.1002/1097-0142(19880901)62:5<989::aid-cncr2820620525>3.0.co;2-u. [DOI] [PubMed] [Google Scholar]
  25. Schwartz B. R., Pinkus G., Bacus S., Toder M., Weinberg D. S. Cell proliferation in non-Hodgkin's lymphomas. Digital image analysis of Ki-67 antibody staining. Am J Pathol. 1989 Feb;134(2):327–336. [PMC free article] [PubMed] [Google Scholar]
  26. Shiraki M., Enterline H. T., Brooks J. J., Cooper N. S., Hirschl S., Roth J. A., Rao U. N., Enzinger F. M., Amato D. A., Borden E. C. Pathologic analysis of advanced adult soft tissue sarcomas, bone sarcomas, and mesotheliomas. The Eastern Cooperative Oncology Group (ECOG) experience. Cancer. 1989 Jul 15;64(2):484–490. doi: 10.1002/1097-0142(19890715)64:2<484::aid-cncr2820640223>3.0.co;2-t. [DOI] [PubMed] [Google Scholar]
  27. Tsushima K., Stanhope C. R., Gaffey T. A., Lieber M. M. Uterine leiomyosarcomas and benign smooth muscle tumors: usefulness of nuclear DNA patterns studied by flow cytometry. Mayo Clin Proc. 1988 Mar;63(3):248–255. doi: 10.1016/s0025-6196(12)65098-8. [DOI] [PubMed] [Google Scholar]
  28. Turner R. R., Layfield L. J., Bishop P. C., Epstein A. L., Parker J. W. Flow cytometric measurements of proliferation-associated nuclear antigen p105 and DNA content in non-Hodgkin's lymphomas. Arch Pathol Lab Med. 1989 Aug;113(8):907–911. [PubMed] [Google Scholar]
  29. Ueda T., Aozasa K., Tsujimoto M., Ohsawa M., Uchida A., Aoki Y., Ono K., Matsumoto K. Prognostic significance of Ki-67 reactivity in soft tissue sarcomas. Cancer. 1989 Apr 15;63(8):1607–1611. doi: 10.1002/1097-0142(19890415)63:8<1607::aid-cncr2820630827>3.0.co;2-1. [DOI] [PubMed] [Google Scholar]
  30. Vindeløv L. L., Christensen I. J., Nissen N. I. A detergent-trypsin method for the preparation of nuclei for flow cytometric DNA analysis. Cytometry. 1983 Mar;3(5):323–327. doi: 10.1002/cyto.990030503. [DOI] [PubMed] [Google Scholar]
  31. Vollmer E., Roessner A., Gerdes J., Mellin W., Stein H., Chong-Schachel S., Grundmann E. Improved grading of bone tumors with the monoclonal antibody Ki-67. J Cancer Res Clin Oncol. 1986;112(3):281–282. doi: 10.1007/BF00395924. [DOI] [PubMed] [Google Scholar]
  32. Vollmer E., Roessner A., Wuisman P., Härle A., Grundmann E. The proliferation behavior of bone tumors investigated with the monoclonal antibody Ki-67. Curr Top Pathol. 1989;80:91–114. doi: 10.1007/978-3-642-74462-4_4. [DOI] [PubMed] [Google Scholar]
  33. Weiss L. M., Strickler J. G., Medeiros L. J., Gerdes J., Stein H., Warnke R. A. Proliferative rates of non-Hodgkin's lymphomas as assessed by Ki-67 antibody. Hum Pathol. 1987 Nov;18(11):1155–1159. doi: 10.1016/s0046-8177(87)80384-2. [DOI] [PubMed] [Google Scholar]

Articles from The American Journal of Pathology are provided here courtesy of American Society for Investigative Pathology

RESOURCES